ABL Bio Inc. (KOSDAQ:298380)
South Korea · Delayed Price · Currency is KRW 39,550
+350 (0.89%)
Nov 2, 2026, 1:02 PM KST
ABL Bio Revenue
ABL Bio had revenue of 19.70B KRW in the quarter ending June 30, 2026, a decrease of -73.99%. This brings the company's total for the last twelve months to 34.28B, down -63.89% year-over-year. In the year 2025, ABL Bio had annual revenue of 79.35B with 137.55% growth. That makes ABL Bio the 32,333rd largest company in the world by revenue and 2,054th in South Korea.
Revenue (ttm)
34.28B
Revenue Growth
-63.89%
P/S Ratio
64.02
Revenue / Employee
336.11M
Employees
102
Market Cap
2.21T
Revenue by Geography
- UK 73.18B 92.2%
- United States 5.77B 7.3%
- South Korea 400.00M 0.5%
Fiscal year ended Dec 31, 2025 See the full ABL Bio breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.35B | 45.95B | 137.55% |
| Dec 31, 2024 | 33.40B | -32.14B | -49.04% |
| Dec 31, 2023 | 65.55B | -1.75B | -2.61% |
| Dec 31, 2022 | 67.30B | 61.97B | 1,162.19% |
| Dec 31, 2021 | 5.33B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| SK Biopharmaceuticals | 861.34B |
| SK bioscience | 659.27B |
| Hugel | 479.57B |
| LigaChem Biosciences | 98.78B |
| HLB Co., Ltd. | 97.47B |
| Komipharm International | 53.02B |
| OliX Pharmaceuticals | 13.64B |
| Peptron | 6.00B |